Skip to main content

Chikungunya Virus

8
Pipeline Programs
5
Companies
7
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
6
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
3100%
+ 11 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Nordic Pharma
Nordic PharmaFrance - Paris
5 programs
1
4
CHIKV VLP vaccinePhase 3Vaccine
CHIKV VLP vaccinePhase 3Vaccine
CHIKV VLP/adjuvantPhase 3
CHIKV VLP/adjuvantPhase 3
CHIKV VLP, adjuvantedPhase 2
Emergent BioSolutions
3 programs
1
2
CHIKV VLP/adjuvantPhase 3
CHIKV VLP/adjuvantPhase 3
CHIKV VLP, adjuvantedPhase 2
Bavarian Nordic
Bavarian NordicDenmark - Kvistgard
4 programs
CHIKV VLP, adjuvantedPHASE_21 trial
CHIKV VLP vaccinePHASE_3Vaccine2 trials
CHIKV VLP/adjuvantPHASE_31 trial
CHIKV VLP/adjuvantPHASE_31 trial
Active Trials
NCT05065983Completed25Est. May 2022
NCT07467707Not Yet Recruiting6,144Est. May 2030
NCT07003984Recruiting720Est. Dec 2028
+2 more trials
Cerus
CerusCA - Concord
1 program
INTERCEPT PlateletsN/A1 trial
Active Trials
NCT02305732Completed90Est. May 2016
Moderna
ModernaCAMBRIDGE, MA
1 program
VAL-181388PHASE_11 trial
Active Trials
NCT03325075Completed60Est. Mar 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Bavarian NordicCHIKV VLP vaccine
Bavarian NordicCHIKV VLP vaccine
Bavarian NordicCHIKV VLP/adjuvant
Bavarian NordicCHIKV VLP/adjuvant
Bavarian NordicCHIKV VLP, adjuvanted
ModernaVAL-181388
CerusINTERCEPT Platelets

Clinical Trials (7)

Total enrollment: 10,710 patients across 7 trials

NCT07467707Bavarian NordicCHIKV VLP vaccine

An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults

Start: May 2026Est. completion: May 20306,144 patients
Phase 3Not Yet Recruiting
NCT07003984Bavarian NordicCHIKV VLP vaccine

A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.

Start: Jun 2025Est. completion: Dec 2028720 patients
Phase 3Recruiting
NCT05349617Bavarian NordicCHIKV VLP/adjuvant

Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years

Start: May 2022Est. completion: Aug 2023413 patients
Phase 3Completed
NCT05072080Bavarian NordicCHIKV VLP/adjuvant

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)

Start: Sep 2021Est. completion: Apr 20233,258 patients
Phase 3Completed
NCT05065983Bavarian NordicCHIKV VLP, adjuvanted

A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine

Start: Oct 2021Est. completion: May 202225 patients
Phase 2Completed
NCT03325075ModernaVAL-181388

Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants

Start: Jul 2017Est. completion: Mar 201960 patients
Phase 1Completed
NCT02305732CerusINTERCEPT Platelets

A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components

Start: Mar 2015Est. completion: May 201690 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 10,710 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.